CA2257596A1 - Antimicrobial agents for oral hygiene products - Google Patents

Antimicrobial agents for oral hygiene products Download PDF

Info

Publication number
CA2257596A1
CA2257596A1 CA002257596A CA2257596A CA2257596A1 CA 2257596 A1 CA2257596 A1 CA 2257596A1 CA 002257596 A CA002257596 A CA 002257596A CA 2257596 A CA2257596 A CA 2257596A CA 2257596 A1 CA2257596 A1 CA 2257596A1
Authority
CA
Canada
Prior art keywords
oil
antimicrobial agent
oral
group
oral hygiene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002257596A
Other languages
French (fr)
Inventor
Lokanathan M. Iyer
James R. Scott
Douglas F. Whitfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philips Oral Healthcare LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2257596A1 publication Critical patent/CA2257596A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42Amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations

Abstract

Oral hygiene compositions include an antimicrobial agent selected from cedarwood oil, chloramphenicol, citronella oil, Glycyrrhiza glabra extract, juicy fruit basil oil, lemon basil oil, and Rosmarinus officinalis oil. Application of these oral hygiene compositions to the oral cavity effectively reduces or prevents the growth of bacteria associated with dental plaque, and with dental caries and/or periodontal diseases such as Actinomyces viscosus, Campylobacter rectus, Fusobacterium nucleatum, Porphyromonas gingivalis, Streptococcus mutans, and Streptococcus sanguis.

Description

CA 022~7~96 1998-12-03 ANTIMICROBIAL AGENTS FOR ORAL HYGIENE PRODUCTS
Field of the Invention The present invention relates to antimicrobial agents for use in oral hygiene products and methods for using such agents.
Back~round of the Invention Periodontal disease and dental caries are of major public health and economic interest worldwide. It is now widely recognized that both of these oral diseases are caused by bacteria which grow in masses on the teeth and in the gingival area. Acommonly used descriptive term for these bacterial masses is "dental plaque". In the case of periodontal disease, Schluger et al. (Schluger, Yuodelis, Page & Johnson, Periodontal Diseases, second edition, pp. 153-262, Lea & Febiger, l'J90) report that dental plaque bacteria, growing in the area where the teeth and gingival tissues meet, cause an infl~mm~tion of the gingiva called "gingivitis". This is characterized by swollen, edematous gingiva ("gums") which are reddened and bleed easily. If plaque removal is inadequate, gingivitis may progress to "periodontitis" or periodontaldisease in many individuals. Periodontitis generally is a characterized by a chronic infl~mm~tion of the tissues around the teeth, which leads to a resorption of supporting bone. Periodontal disease is the leading cause of tooth loss among adults.
Dental caries (cavities) are also caused by bacteria, with Streptococcus mutans being ~ 20 the principal etiologic agent (McGhee, Michalek & Cassell, Dental Microbiology, p. 279, Harper & Row, 1982).
- The prevention of dental plaque or the removal thereof has long been the focus of development with the ultimate goal of inhibiting both caries and periodontal diseases. While the formation of dental plaque can be inhibited to a certain extent by CA 022~7~96 1998-12-03 brushing the teeth at frequent intervals, brushing alone is not sufficient to effectively prevent the formation of dental plaque or remove substantially all of the dentalplaque that has formed on the teeth.
Since brushing alone is not suI'i'icient to prevent and remove plaque, chemical methods using antibacterials such as chlorhexidine, benzalkonium chloride, and cetylpyridinium chloride have been proposed. In addition, the use of natural products for the treatment of teeth and gums is old in the art, having been practiced and documented since the mid-1880s. Since thcn, numerous patents have disclosed compositions of oral products containing natural product extracts. There are numerous natural essential oils available. Many of these oils are described in KIRK
OTHMER ENCYCLOPEDIA OF CHEMICAL TECHNOLOC~Y, 4th ed., vol. 17, pp. 603-674, John Wiley & Sons, Inc. Morton Pader, in "Oral l-Iygiene Products and Practice,"Cosmetic Science and Technology Series. vol. 6, at pp. 356-373, Marcel Dekker, Inc., describes sanguinaria extract as an anti-plaque agent with antimicrobial properties.
Pader also describes that volatile oils such as eucalyptol, menthol, thymol, methylsalicylate have varying degrees of antimicrobial activity, and antiplaque activity has been reported under appropriate test conditions. Pader describes that cinnamon oil is a very weak antiseptic, and that eucalyptus oil and eucalyptol are antiseptic. Padcr notes that some essential oils are used in othcr products primarily for flavor. Among these are cinnamon, cassia, clove, thyme, peppermint, anise and anethol. Pader also describes that these essential oils have detectable antimicrobial activity.
For example, it is known that cocamidopropyl betaine, hinokitiol, and berberine and the essential oils, citral, geraniol, and 3uniper berries oil individually exhibit antimicrobial properties against certain bacteria.
U.S. Patent No. 3,940,476 describes a method for inhibiting the formation of dental plaque, which comprises topically applying to the teeth as an active ingredient an amount of either one or a combination of (a) allyl isothiocyanate, (b) uranine, (c) obtusastyrene, (d) citral, (e) citronellol, (f) nerol, or (g) geraniol.
U.S. Patent No. 4,913,895 describes an oral composition including a linear polyphosphate or a cyclic polyphosphate and menthol, anethol, or mixtures thereof in an aqueous medium. The composition is reported to have antibacterial effects andprevent the development of calculus and periodontal diseases.
U.S. Patent No. 4,966,754 describes that certain essential oils and combinations thereof possess antimicrobial properties against Aspergillus niger, CA 022~7~96 1998-12-03 Candic~a albicans, Staphylococcus aureus, and Pseudomonas aeruginosa, and therefore are suitable as preservatives in cosmetic compositions. A blend of 14 essential oils is described as providing desirable antimicrobial properties against the notcd microorg~ni~.m~.
U.S. Patent No. 4,999,184 describes oil compositions containing certain pyrophosphate salts which are reported to provide an anticalculus benefit.
U.S. Patent No. 5,316,760 describes a mouth care product that contains a combination of Urtica dioica extract and an extract of Juniperus communis. The combination of these extracts is described as leading to a synergistic reduction of both dental plaque and bleeding or inflamm~tion of the gingiva. Achillaea millefolium extract is also described as being a suitable additive to the combination of the Urtica dioica and Juniperu~ communis extracts.
U.S. Patent No. 5,472,684 describes a composition including thymol and eugenol, and optionally a sesquiterpene alcohol, such as farnesol, that reportedly has antiplaque and antigingivitis effects. Australian tea tree oil, sage oil, and eucalyptol are described as enhancing the antiplaque and antigingivitis activity of mouth rinses formulated from the disclosed compositions.
One property that characterizes the effectiveness of an antimicrobial agent as an antiplaque and anticalculus agent is the minimum inhibitory concentration, orMIC, of the agent. The MIC is the minimum concentration in micrograms per milliliter of an antimicrobial agent at which no bacterial growth are observed. At concentrations below the MIC, an antimicrobial agent is ineffective at killing or inhibiting the growth and reproduction of bacteria. At concentrations above the MIC, an antimicrobial agent is effective at killing or inhibiting the growth andreproduction of bacteria.
Typicaliy, antimicrobial agents are introduced into the oral cavity at an initial concentration. Almost immediately, the initial concentration begins to decrease because of the dynamics of the oral cavity. Eventually, the concentration of theantimicrobial agent within the oral cavity will fall below the MIC. Thus, it has been a goal of those working to develop antiplaque and anticalculus formulations to use antimicrobial agents that ha~e low MICs.
Chlorhexidine has a MIC of about one ~lg/ml and is the standard against which other antimicrobial agents are measured. While chlorhexidine has a desirable MIC, it also exhibits undesirable taste and has the undesirable side effect of staining 3 5 teeth.

CA 022~7~96 1998-12-03 WO 98/44901 PCT/US98tO6470 Summar~/ of the Invention In one aspect, the present invention is an oral hygiene composition that includes an antimicrobial agent selected from cedarwood oil, chloramphenicol, citronella oil, Glycyrrhiza glabra extract, juicy fiuit basil oil, lemon basil oil, and 5 Rosmarinus of,~icinalis oil. According to the present invention, oral hygiene compositions including these antimicrobial agents are effective at inhibiting and preventing the growth of bacteria present in oral cavities such as Actinomyces viscosus, Fusohacterium nucleatum, Porphyromonas gingivali~, Streptococcus mutans, and Streptococcus sanguis. Oral hygiene compositions formed in 10 accordance with the present invention are characterized in that the antimicrobial agent is present in an amount sufficient to retard the growth of bacteria or kill bacteria.
Thc antimicrobial agents can be combined with components typically found in oral hygiene products such as dentifrices. These components include abrasives, 15 humectants, binders, and surfactants. Other dentifrice components include flavoring agents and thickening agents.
In accordance with the present invention, the oral hygiene compositions and products of the present invention can be used in the method of practicing oral hygiene that includes the step of contacting an oral cavity with an antimicrobial agent 20 selected from cedarwood oil, chloramphenicol, citronella oil, Glycyrrhiza glabra extract, juicy fruit basil oil, lemon basil oil, lemon oil, or Rosmarinus officinali.s oil.
Detailed Descri~tion of the Preferred Embodiment As used herein, the following terms have the following meanings.
"Cedar~,vood oil" refers to volatile whole oil extracts from the heartwood of 25 Juniperus virginiana or Juniperis ashei. Constituents of the whole oil extract include thujopsene, cedrol, alpha-copaene, alpha-cedrene, beta-cedrene and widdrol. The CAS number for cedarwood oil is 8000-27-9.
"Chloramphenicol" refers to 2,2-dich]oro-N-[2-hydroxyl-1-(hydroxymethyl)-2-(4-nitrophenyl) ethyl] acetamide. Chloramphenicol is derived from Streptomyces30 vene~uelae or by organic synthesis. The CAS number for chloramphenicol is 56-75-7.
"C~itronella oil" refers to a commercially available oil produced by steam distillation of either Cymbopogon nardu.s or Cymhopogon winterianus. The CAS
number for citronella oil is 8000-29-1.

CA 022~7~96 1998-12-03 "Glycyrrhiza glabra extract", also known as licorice root extract, refers to thecrude powder extract from Glycyrrhiza glabraL. Several varieties including G. typica and G. ~landuli,fera exist. Glycyrrhiza glabra extract contains glycyrrhizic acid and glycyrrhetinic acid. The whole extract is available from commercial sources or may be collected by solvent extraction, such as ethanol extraction described below.
"Juicy fruit basil oil" refers to the whole extract of a selected variety of basil with a juicy fruit component. Juicy fruit basil is a cultivar of Ocimum bascilicum L.
"Lemon basil oil" refers to the volatile whole oil extract from a selected variety of basil with a citral component. Lemon basil is a cultivar of Ocimum bascilicum L. with a high content of citral.
"Lemon oil" refers to the volatile whole oil extract from the fresh peel of Citrus limon. Lemon oil is also known as oil of lemon or citrus limon oil. The CAS
number for lemon oil is 8008-56-8.
"Rosmarinus officinalis oil" refers to the whole oil extract from the flowering tops of Rosmarinus officinalis. Rosmarinu~s o,,fficinali.s oil is also known as the extract of Rosemary, or the extract of Rosmarinus officinalis oil. The CAS number for Rosmarinus officinalis oil is 84604-14-8.
All of the foregoing are available from commercial sources.
"Minimal inhibitory concentration or MIC" refers to the minimum concentration in micrograms per milliliter of an antimicrobial agent at which nobacterial growth are observed. At concentrations below the MIC, the antimicrobial agent is ineffective at killing or inhibiting the growth and reproduction of bacteria.
At concentrations above the MIC, the antimicrobial agent is effective at killing or inhibiting the growth and reproduction of bacteria.
An oral hygiene composition formed in accordance with the present invention includes an antimicrobial agent selected from cedarwood oil, chloramphenicol, citronella oil, Glycyrrhiza glabra extract, juicy fruit basil oil, lemon basil oil, and Rosmarinus officinalis oil. These oral hygiene compositions can be incorporated into oral hygiene products formulated in accordance with the present invention, such as ~ dentifrices, mouth washes, and mouth rinses.
Preferred oral hygiene compositions include an antimicrobial agent selected from cedarwood oil, chloramphenicol, and Glycyrrhiza glabra extract. Particularly preferred f'or incorporation into an oral hygiene composition formulated in accordance with the present invention are antimicrobial agents selected from CA 022~7~96 1998-12-03 cedarwood oil and Glycyrrhiza glabra extract. The preferred antimicrobial agentsare selected because these agents are surprisingly eff'ective at retarding the growth of and/or preventing the growth of representative gram-positive and gram-negative oral pathogenic bacteria such as ~l ctinomyces vlscosus, Fusobacterium nucleal tlm, 5 Porphyro~lonas gingivalis, Strept(lcoccus mutan~, and Streptococcus sanguis. The examples that follow illustrate the effectiveness that the antimicrobial agents of the present invention have against these particular bacteria. Pref'erably, the antimicrobial a~ent is effectivc against more than one of the bacteria noted above, and preferably all of the bacteria noted above.
The particular amount of antimicrobial agent present in compositions formed in accordance with the present invention is not limited to any particular value,provided that the amount present is effective at retarding the gro~vth of bacteria and/or preventing the growth of bacteria, i.e., an amount that is greater than the MIC
of the antimicrobial agent with respect to the particular bacteria.
As illustrated in the examples that follow, the antimicrobial agents of the present invention exhibit MICs that range from about 3.1 to about 156 against the representative oral pathogens Actinomyces viscosus, Fllsobacterium nucleatum, Porphyromona3 gingivalis, ~Slrept-)coccus mutans, and Streplococcu.s sanguis.
Dentifrices, or toothpastes, are generally a thickened slurry of an abrasive polishing material in an aqueous humectant system. Typically, dentifrices include an abrasive to remove stained pellicle, humectant(s) to provide a vehicle for the flavor, abrasive, thickening agent(s) to structure and stabilize the dentifrice, surfactant mainly to supply foam during use, fluoride to prevent dental caries, and flavor to make the product taste pleasant.
Numerous abrasives are available for use in dentifrices, examples include silica xerogel, silica precipitates, dicalcium phosphate, dicalcium phosphate dihydrate, alumina trihydrate, calcium pyrophosphate, calcium carbonate, and insoluble sodium metaphosphate.
Examples of suitable humectants include sorbitols, glycerin, and polyethylene glycols.
Silica aerogels, pyrogenic silica, silica precipitates, carboxymethylcellulose, carboxyvinyl polymers, xanthan gum, and carrageenan are examples of materials that are suitable as thickeners.
Exemplary surfactants include sodium lauryl sulfate and dodecylbenzene 3 5 sulfonate.

CA 022~7~96 1998-12-03 Numerous flavoring agents are commercially available with those providing mint or other refreshing flavors such as cinnamon being commonly used.
Oral rinses or mouth washes are generally, aqueous, pourable emulsions of flavors into which, in most instances, an antimicrobial has been incorporated.
Typical components of an oral rinse include flavoring agent to make the product pleasant to use and to emphasize therapeutic or freshness qualities, surfactant(s) to maintain flavor in stable dispersion, humectant(s) to improve mouth feel, thickening agent, and an active agent. Often times, a surfactant is used to impart light foaming properties to the oral rinse.
Dentifrices and oral rinses incorporating the antimicrobial agents for inhibiting the growth of bacteria in the oral cavity in accordance with the present invention are forrnulated in a conventional manner with the antimicrobial agentsbeing present in an amount ranging from about 0.001 wt. % to about 5.0 wt. % based on total weight of dentifrice. Preferably the antimicrobial agents are present in an amount ranging from about 0.01 wt. % to about 2.5 wt. %. The specific componentsused in the dentifrices and oral rinses incorporating the antimicrobial agents of the present invention are not limited to those set forth above; however, the components selected preferably do not have an antagonistic effect on the antimicrobial properties of the selected antimicrobial agent.
The following examples illustrate the effectiveness of oral hygiene compositions of the present invention against bacteria present in the oral cavity, the MIC for the antimicrobial agents in the compositions against such bacteria, dentifrice forrnulations including antimicrobial compositions of the present invention, consumer preference for such dentifrice formulations, and in vivo effectiveness data for such dentifrice formulations.
Example 1 Determination of Minimum Inhibitory Concentration of Antimicrobial A,eents The following example illustrates how antimicrobial agents useful in accordance with the present invention retard or prevent the growth of dental plaque bacteria present in the oral cavity. In addition, the example illustrates the lowest ~ concentration of various antimicrobial agents that will inhibit visible in vitro growth of a particular bacteria.
The assay used a microtiter plate to dilute the antimicrobial agent to varying concentrations in order to determine the MIC.

CA 022~7~96 1998-12-03 Table 1 below provides a listing of antimicrobial agents used in this example and abbreviations therefor.
Table I
Antimicrobial A-Jents and Abbreviations Therefor cedarwood oil (RCl) chloramphenicol (CRI) citronella oil (CTRI ) C~lycyrrhiza glabr~l extract (GLY) juicy fruit basil oil (JFB I ) lemon basil oil (LMB I ) Ro.smari~us of~icinalis oil (ROFI) A bacteria culture was incubated overnight at 37~C. Prior to dilution of the antimicrobial agents as described below, the bacterial culture was spun down at 2000 rpm into a pellet and resuspended in a solution of buffered phosphate. The innoculum was normalized with a spectraphotometer to an optical density at 550 nanometers of between 0.18-0.22, equivalent to 5.0 x 107 colony-forming units (CFU per milliliter). The innoculum was set aside until the completion of the antimicrobial agcnt dilution.
A sterile polystyrene 96-well plate was used to dilute the antimicrobial agents. Usiny aseptic technique, 100 microliters of distilled water was placed in each test well. In the first well in each column, 100 microliters of antimicrobial agent was added. Stock solutions of antimicrobial agents were prepared with methanol as a solvent to bring the agents into solution. This resulted in a one-half dilution of the stock solution. 100 microliters from these wells was then transferred to the next well in the column, and so on, down each column. Each transl'er accomplished a one-half dilution of the concentration in the prece-ling well. After the dilution of the antimicrobial agent was completed, 80 microliters of growth media specific for the bacteria under study was added to each well. The specific growth media for a given bacteria are set forth in Table 2.
Next, 20 microliters of innoculum was added to each well. This resulted in the first well of each column having a final dilution of one quarter of the stock solution. The remaining wells were a one-half dilution of the preceding well for each transfer.
The 96-well plate was incubated under conditions that varied depending on the particular microorganism. Thc incubation conditions are set forth in Table 2.

CA 022~7~96 1998-12-03 The aerobic bacteria were incubated under normal room conditions and the anaerobic bacteria were incubated under an atmospherc of 10% hydrogen gas, 5% carbon dioxide gas and the balance nitrogen gas. Following 48 hours of incubation, the incubated plate was read for microbial gro~-vth with a spcctraphotometer by optical 5 density (OD). The welJ containing the lowest dilution achievable with a spectraphotometer reading below 0.05 OD (i.e., no detectable microbial growth) was considered representative for the antimicrobial agcnt. The MIC for the agent wasdetermined by accounting for the starting stock solution concentration and the resulting dilutions in the 96-well plate.
The specific bacteria inoculated into the 96-well plate are set t'orth in Table 2 below, along with the growth media and incubation conditions for that microorganism.
Table 2 Microor~ni~m~lGrowth Media/Incubation Conditions ATCC Growth Microorganism No. Media Incubation Conditions Campylohacter rectus 33238 CR media4 48 hrs/37~C/anaerobic Actinomyces l~iscosus (AV) 19246 TSB~ 48 hrs/37 C/aerobic Fusobacterium nucleahlm (FN)10933FN media3 48 hrs/37~C/anaerobic l'orphyromonas gingivalis (PG) 33277 PG media2 48 hrs/37~ClanaerobicStreptococcus mutans (SM) 25175 TSBl 48 hrs/37 Claerobic Streptococcus sanguis (SS) 49295 TSB' 48 hrsl37 Claerobic Tryptic Soy Broth 3.0% wt. to vol., yeast extract 0.1%, and 999 milliliters distilled water.
2 Tryptic Soy Broth 3.0% wt. to vol., yeast extract 0.5%, L-cystein 0.05%, Hemin 0.0005%, Menadione 0.00002%, and 990 milliliters distilled water.
3 Tryptic Soy Broth 3.0% wt. to vol., yeast extract 0.5%, Peptone 1.0%, L-cystein extract, 20 Hemin 0.0005%, Menadione 0.00002%, and 990 milliliters distilled water.
4 Brain Heart Infusion Broth 0.74% wt. to vol., yeast extract 0.01%, sodium formate 0.2%, sodium fumerate 0.03%, hemin 0.005% and 990 millileters distilled water.
In the following tables, the antimicrobial agents are identified with respect tothe abbreviations set forth in Table 1. In addition, the five microor~ni~m~ set forth 25 in Table 2 are referred to by the abbreviations set forth in Table 2.

CA 022~7~96 1998-12-03 Table 3 MTC (!lg/ml) for Antimicrobial A~ents for lndicated Bacteria Agent AV CR FN PG SM SS
RCl 31.331.3 31.3 7.8 31.3 15.6 CR1 3.1 - 3.1 6.3 3.1 3.1 CTRl 62.5 125 31.3 31.3 62.5 31.3 GLY 15.615.6 15.6 7.8 15.6 7.8 JFB1 156.3156.3 156.3 62.5 156.3 156.3 LMOI 312.5125 62.5 31.3 125 125 LCCI 312.5125 156.3 78.1 156.3 156.3 ROF1 125 125 62.5 62.5 125 125 This example illustrates the minimum inhibitory concentration of the noted S antimicrobial agents and the ability of thc antimicrobial agents to inhibit growth of the specific bacteria.
Example 2 Dentifrice Formulations This example describes dentifrice formulations comprising antimicrobial 10 agents of the present invention. Formulation 18-88 does not include antimicrobial agents in accordance with the present invention.
Table 4 Formulation 5-82: 0.1% Cedarwood Oil (W/W) Component Weight Percent Sorbitol 70% 37 00 Poloxamer 407 (PLURONIC(~ F127) 9.50 Deionized Water 24.50 Carbomer g40 (CARBOPOL(~) 940)0.30 Sodium Hydroxide 0.20 wo 98/44901 PCT/USg8/06470 Component Weight Percent Xanthan Gum 0.40 Glycerin 4.75 Sodium Fluoride 0.25 Sodium Saccharin 0.30 SYLODENT~' 750 (silica) 9.50 SYLODENT~' 15 (silica) 9.50 Cedarwood oil 0.50 Flavor 0.90 FD&C Blue #l 1% solution 0.10 Titanium Dioxide 0.90 Sodium Lauryl Sulfate l 40 Table 5 Formulation 5-81: 0.1 % Cedarwood Oil (W/W) Component Weight Percent Sorbitol 70% 58.63 Sodium Carboxymethylcellulose 0.35 Deionized Water 3.00 Polyethylene Glycol 600 5.00 Glycerin 10.00 Sodium Fluoride 0.22 Sodium Saccharin 0.30 Sodium Benzoate 0.50 SYLODENT~ 700 (silica) 15.00 AEROSIL~3 200 (silica) 3.00 Component Weight Percent Flavor 0.80 Ethanol 1 .50 Cedarwood 0. 10 I;D&C Blue #1 1% solution 0.10 Sodium Lauryl Sulfate 1.50 Table 6 Formulation 5-1()8: 0.4% Cedarwood Oil (W/W) Component Weight Percent Sorbitol 70% 50.00 Deionized water 24.63 Carbomer 940 (CARBOPOL(~ 940)0.30 Sodium hydroxide 0.20 Xanthan gum 0.500 Sodium fluoride 0.22 Sodium saccharin 0.55 SYLODENT(~) 750 (silica) 10.00 SYLODENT(~) 15 (silica) 10.00 Cedarwood oil 0.40 Flavoring agents 0.80 Titanium dioxide 1.00 Sodium lauryl sulfate 1.40 Table 7 Formulation 1 X-87: 0.5% Glvcyrrhiza ~labra Extract (W/W) Component Weight Percent Sorbitol 70% 50 00 Deionized water 24.53 Carbomer 940 (CARBOPOL(~) 940) 0.30 Sodium hydroxide 0.20 Xanthan gum 0 50 Sodium fluoride 0.22 Sodium saccharin 0.55 SYLODENT(~) 750 (silica) 10.00 SYLODENT(fi) 15 (silica) 10.00 Glycyrrhiza glabra extract 0.50 Flavoring agents 0.80 Titanium dioxide I .00 Sodium lauryl sulfate 1.40 Table 8 Formulation 18-90: ] % Cedarwood Oil (W/W) Component Weight Percent Sorbitol 70% 50 00 Deionized water 24.03 Carbomer 940 (CARBOPOL6) 940) 0.30 Sodium hydroxide 0.20 Xanthan gum 0.50 Sodium fluoride 0.22 Sodium saccharin 0.55 SYLODENT~' 750 (silica) 10.00 SYLODENT~) 15 (silica) 10.00 CA 022~7~96 1998-12-03 Component Weight Pcrcent Cedarwood oil 1.00 Flavoring agents 0.80 Titanium dioxide 1.00 Sodium lauryl sulfate 1.40 Table 9 Formulation 18-25: 0.1% Hinokitiol Component Weight Percent Deionized Water 92.02 Carhomer 940 (CARF~OI'OI ('~ 940) 1.00 Sodium Hydroxide 0.75 Sodium Saccharin 0.50 Sodium Fluoride 0.23 Flavor 0. 80 Hinokitiol 0 10 Ethanol 3 50 Sodium Lauryl Sulf'ate 1.10 CA 022~7~96 1998-12-03 Table 10 Formulation 18-88: Control Component Weight Percent Sorbitol 70% 37.70 Poloxamer 407 (PLURONIC(~ F 127) 9.50 Deionized Water 25.50 Carbomer 940 (CARBOPOL(~) 940) 0.30 Sodium Hydroxide 0.20 Xanthan Gum 0.40 Glycerin 4.75 Sodium Fluoride 0.25 Sodium Saccharin 0.40 SYLODENT~' 750 (silica) 9.50 SYLODENT~) 15 (silica) 9.50 Titanium Dioxide 1.00 Sodium Lauryl Sulfate 1.00 "Carbomer" refers to a polymer composed of acrylic acid crosslinked with allyl sucrose available as CARBOPOL(~)940. CARBOPOL(}'940is commercially available from B.F. Goodrich. SYLODENT~) 750 and 700 are silica gels (silicon dioxide), and SYLODENT(~lSis a silica gel (silicon dioxide). SYLODENT(E~is available commercially from W.R. Grace & Co. Conn. Davison Chemical Division.
The formulations described above are formed in a vacuum mixer by adding deionized water and dispersing the Carbomer while pulling a vacuum. When the Carbomer was well dispersed, the sodium hydroxide was added. The 70% sorbitol and Poloxamer were heated and mixed in another vessel. The Poloxamer mixture was then added to the vacuum mixer and blended with the Carbomer mixture.
Xanthan gum was mixed with glycerin and then added to the solution in the vacuummixer and incorporated therein. The salts were then added to the vacuum mixer CA 022~7~96 1998- 12-03 WO 98/4490~ PCT/US98/06470 followed by the silicas. These components were slowly mixed in. Next7 the activeagents flavoring agents, sodium lauryl sulfate and coloring agents were added followed by mixing until well incorporated.
This exarnple illustrates several dentifrice formulations incorporating 5 antimicrobial agents of the present invention.
Example 3 Customer l~cccptance This example illustrates customer acceptance of dentifrice formulations incorporating an antimicrobial agent in accordance with the present invention.
The i'ormulations set forth above in Tables 4-9 were evaluated for customer acceptance. For comparison purposes, several commercially available dentifrices were also e~Jaluated. These included Viadent Gel (Formulation ~-35), availablc from Viadent, Inc.; Crest Regular Blue Paste (Formulation 5-97), available *om Proctor &
Gamble Company; and Listerine Teal Gel (Formulation 5-99), available from Warner1 5 Wellcomc.
The preference study was carried out with a group of approximately 20 peoplc. One tube of dentifrice formulation was given to cach person to use over the course of a weck. At the end of the week, participants filled out a questionnaire, the results of which are summarized in Table 1 I below. The scoring range was 1-10,~0 with 1 bein~ "poor" and 10 being "good." The scores were tallied and averaged.
Table 1 1 Consumer Evaluation Formulation 5-82 5-81 5-108 5-35 5-97 5-99 Color 6.61 8.00 6.75 2.72 6.64 7.25 Appearance 6.42 7.90 6.90 3.16 6.62 6.75 Taste 5.80~ 6.20 7.15 3.72 6.27 4.00 After Taste 6.80 5.85 6.05 3.38 6.09 3.85 Aroma 7.19 6.79 7.05 4.33 6.32 4.5S
Cleaning 7.38 5.95 7.00 3.94 6.41 6.10 Foam 6.42 5.10 7.55 3.66 6.05 5.85 CA 022~7~96 1998-12-03 Fonnulation 5-82 5-81 5- 108 5-35 5-97 5-99 Consistency 7.23 5.95 7.70 4.00 6.14 5.75 Dry Mouth 8.14 6.90 7.10 3.89 7.91 5.70 Next Morning Feel 7.00 6.16 7.05 3.39 5.50 5.15 Overall Mouth Feel 7.33 6.16 7.05 3.11 6.09 4.45 Overall Satisfaction 6.90 6.10 6.90 3.05 5.95 4.20 This example illustrates how the overall consumer satisfaction for the formulations with active agents in accordance with the present invention is greater than the overall consumer satisfaction for certain commercially available products.
Example 4 S In Vivo Gin~ival ~argin Bacterial Reduction This example illustrates how dentifrice formulations including compositions of the present invention reduce bacteria levels in the gingival margin.
In this example, the subject's brushing habits remained constant. On the day of sampling, subjects had not brushed their teeth for 16-18 hours (overnight) prior to testing. The level of bacteria was enumerated by recovering in vivo samples and counting the number of bacterial colonies forrned on agar after 48 hours.
Subjects were 18-65 years old, had a minimum of 20 teeth, and had normal salivary flow. Subjects were rejected if they had systemic diseases that affect the oral tissues, such as diabetes, blood cell abnormalities, Down's syndrome, or known HIV-infection; had glossitis, moderate to severe gingivitis, periodontitis or other oral infections, or were taking a systemic antibiotic or had done so in the two weekspreceding the initiation of the test.
Each of the formulations was assayed for antimicrobial efficacy on approximately 20 subjects. The subjects were requested to have overnight plaque the morning they were sampled for a "single brushing effect" of a formulation.
At baseline, a gingival margin plaque sample was taken with a sterile cotton swab and placed in I milliliter of sterile phosphate buffered saline (PBS). Swabs were gently rubbed along the gingival margin of the mandibular buccal surface between the incisors. Subjects then brushed immediately after the baseline sample with a dentifrice formulation using an electric toothbrush for two minutes. At CA 022~7~96 1998-12-03 WO 98/4~901 PCT/US98/06470 intervals of one and two hours after completion of the brushing, gingival plaquesamples were recovered with swabs as described above.
The clinical design was a multi-period crossover study. By multi-period crossovcr study is meant an experiment in whicll subjects are ~lministered first one treatment, then "crossed over" to receive a second, then third and finally a fourth treatment. The experimental design enables each subject to serve as his or her own control. A "wash-out" period of 2 days was used between testing different antibacterial f'ormulations.
The gingival samples were placed in test tubes and remained at room temperature until processed within one hour. The test tube samples were seriallydiluted in sterile PBS with a Spiral Plater (Spiral Systems, Cincinnati, Ohio) and plated on blood agar supplemented with 5% sheep blood (BBL, Becton Dickinson, Cockeysville, Maryland). The plated samples were then incubated aerobically at 37~C for 48 hours. Bacteria were counted for total aerobic colony forming units.The bacterial counts were transformed into logl0 units. Mean and standard deviations for each test condition were generated. Data was paired by subject for relevant comparisons and analyzed by the nonparametric Wilcoxon sign-rank test for significance level. Hypothesis testing relied on statistics utilizing the multiperiod crossover design of the clinical study.
The data are presented below in Table 12. Formulations 18-25, 18-87, and 18-90 included components set forth in Tables 9, 7 and 8, respectively.
Formulatioll 18-88 included the components set forth in Table 10 (no antibacterial agent) and was used as a control for comparison purposes against formulations 18-25, 18-87 and 18-90.

CA 022~7~96 1998-12-03 Table 12 Effect of Antimicrobial A~ent Containin~ Dentifrice Formulations on In Vivo Bacterial Levels % ~/o Number Conc.(Ix10 C~U/ml)Bacterial . . of Formul- Active Slgnlficance wt./ . Reduction Subjects ation Ingredient Tlme: Level wt. vs. Control in Trial Baseline 2 hrs.
18-25 Hinokitiol 0.1 33.11 4 47 49.8% ** 17 18-87 Glycyrrh~za 0.5 39.81 2.14 76.0% *** 17 gl~bra ext.
18-90 Cedarwood1.0 31.62 3.1664.5% *** 17 18-88 Con~ol -- 33.88 8.91NA NA 17 Statistical Results: Significance testing was against Control (formulation 18-88) at 2 hours.
Wilcoxon sign-rank matched pairs with log,0 transfonned data.
***p<o ol, **p<0.05, *p<O.l NA = Not Applicable 10This example illustrates how the dentifrice formulations including antimicrobial agents of the present invention reduce gingival in vivo bacterial levels.
Example 5 Ethanol Extraction of Glvcyrrhiza glabra 25 grams of powdered plant material from Glycyrrhiza glabra was combined 15with 250 grams of a 95:5 ethanol/water mixture. The mixture was stirred overnight at room temperature. Solids were removed from the stirred mixture with a No. 4 Whatman filter in a Buchner funnel. Further removal of solids was achieved with a No. 5 Whatman filter in a Buchner funnel. Additional solids were removed with a Whatman I micrometer filter in a Buchner funnel. A vacuum filtration apparatus and a 0.2 micrometer filter was employed to clean the solution a final time. The clean solution was then concentrated down to a solid using a rotovaporizer.

Approximately, 2.5 grams of a rust colored solid was collected as the crude extract of Glycyrrhiza glcrbra.
While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes can be made therein without 5 departing from the spirit and scope of the invention.

Claims (27)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. An oral hygiene composition comprising:
an antimicrobial agent selected from the group consisting of cedarwood oil, chloramphenicol, citronella oil, Glycyrrhiza glabra extract, juicy fruit basil oil, lemon basil oil, and Rosmarinus officinalis oil.
2. The oral hygiene composition of Claim 1, wherein the antimicrobial agent is selected from the group consisting of cedarwood oil, chloramphenicol. and Glycyrrhiza glabra.
3. The oral hygiene composition of Claim 2, wherein the antimicrobial agent is selected from the group consisting of cedarwood oil and Glycyrrhiza glabra.
4. The oral hygiene product of Claim 1, wherein the antimicrobial agent is present in an amount effective to retard growth of oral pathogenic bacteria.
5. The oral hygiene composition of Claim 4, wherein the oral pathogenic bacteria are selected from the group consisting of Actinomyces viscosus, Campylobacter rectus, Fusobacterium nucleatum, Porphyromonas gingivalis, Streptococcus mutans, and Strepfococcus sanguis.
6. The oral hygiene composition of Claim 1, wherein the antimicrobial agent is present in an amount effective to kill bacteria.
7. The oral hygiene composition of Claim 6, wherein the bacteria are selected from the group consisting of Actinomyces viscosus, Campylobacter rectus, Fusobacterium nucleatum, Porphyromonas gingivalis, Streptococcus mutans, and Streptococcus sanguis.
8. The oral hygiene composition of Claim 1, wherein the antimicrobial agent is present in an amount effective to inhibit the formation of dental plaque.
9. The oral hygiene composition of Claim 1, wherein the antimicrobial agent is present in an amount greater than the minimum inhibitory concentration of the agent.
10. A dentifrice comprising:
an antimicrobial agent selected from group consisting of cedarwood oil, chloramphenicol, citronella oil, Glycyrrhiza glabra, juicy fruit basil oil, lemon basil oil, lemon oil, and Rosmarinus officinalis oil;
an abrasive;
a humectant;
a binder; and a surfactant.
11. The dentifrice of Claim 10, wherein the antimicrobial agent is selected from the group consisting of cedarwood oil, chloramphenicol, and Glycyrrhiza glabra.
12. The dentifrice of Claim 11, wherein the antimicrobial agent is selected from the group consisting of cedarwood oil and Glycyrrhiza glabra.
13. The dentifrice of Claim 10, wherein the antimicrobial agent is present in an amount effective to retard growth of oral pathogenic bacteria.
14. The dentifrice of Claim 13, wherein the bacteria are selected from that group consisting of Actinomyces viscosus, Campylobacter rectus, Fusobacterium nucleatum, Porphyromonas gingivalis, Streptococcus mutans, and Streptococcus sanguis.
15. The dentifrice of Claim 10, wherein the antimicrobial agent is present in an amount effective to kill oral pathogenic bacteria.
16. The dentifrice of Claim 15, wherein the oral pathogenic bacteria are selected from the group consisting of Actinomyces viscosus, Campylobacter rectus, Fusobacterium nucleatum, Porphyromonas gingivalis, Streptococcus mutans, and Streptococcus sanguis.
17. The dentifrice of Claim 10, wherein the antimicrobial agent is present in an amount effective to inhibit the formation of dental plaque.
18. The oral hygiene product of Claim 10, wherein the antimicrobial agent is present in an amount greater than the minimum inhibitory concentration of theagent.
19. A method for practicing oral hygiene comprising the step:
contacting an oral cavity with an antimicrobial agent selected from the group consisting of cedarwood oil, chloramphenicol, citronella oil, Glycyrrhiza glabra, juicy fruit basil oil, lemon basil oil, lemon oil, and Rosmarinus officinalis oil.
20. The method of Claim 19, wherein the antimicrobial agent is selected from the group consisting of cedarwood oil, chloramphenicol, and Glycyrrhiza glabra.
21. The method of Claim 18, wherein the antimicrobial agent is selected from the group consisting of cedarwood oil and Glycyrrhiza glabra.
22. The method of Claim 19, wherein the contacting step further comprises contacting the oral cavity with an amount of the antimicrobial agent effective to retard growth of oral pathogenic bacteria.
23. The method of Claim 22, wherein the oral pathogenic bacteria selected from the group consisting of Actinomyces viscosus, Campylobacter rectus, Fusobacterium nucleatum, Porphyromonas gingivalis, Streptococcus mutans, and Streptococcus sanguis.
24. The method of Claim 19, wherein the contacting step further comprises contacting the oral cavity with an amount of the antimicrobial agent effective to kill oral pathogenic bacteria.
25. The method of Claim 24, wherein the oral pathogenic bacteria is selected from the group consisting of Actinomyces viscosus, Campylobacter rectus, Fusobacterium nucleatum, Porphyromonas gingivalis, Streptococcus mutans, and Streptococcus sanguis.
26. The method of Claim 19, wherein the contacting step further comprises contacting the oral cavity with an amount of the antimicrobial agent effective to inhibit the formation of dental plaque.
27. The method of Claim 19, wherein the contacting step further comprises contacting the oral cavity with an amount of the antimicrobial agent greater than the minimum inhibitory concentration of the antimicrobial agent.
CA002257596A 1997-04-04 1998-04-01 Antimicrobial agents for oral hygiene products Abandoned CA2257596A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82552597A 1997-04-04 1997-04-04
US08/825,525 1997-04-04

Publications (1)

Publication Number Publication Date
CA2257596A1 true CA2257596A1 (en) 1998-10-15

Family

ID=25244223

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002257596A Abandoned CA2257596A1 (en) 1997-04-04 1998-04-01 Antimicrobial agents for oral hygiene products

Country Status (14)

Country Link
EP (1) EP0921784A1 (en)
JP (1) JP2000512660A (en)
KR (1) KR20000016351A (en)
CN (1) CN1225576A (en)
AU (1) AU6877398A (en)
BR (1) BR9804814A (en)
CA (1) CA2257596A1 (en)
CZ (1) CZ384898A3 (en)
HU (1) HUP0001257A2 (en)
IL (1) IL127259A0 (en)
NO (1) NO985644L (en)
NZ (1) NZ333146A (en)
SK (1) SK162898A3 (en)
WO (1) WO1998044901A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248309B1 (en) * 1997-04-04 2001-06-19 Optiva Corporation Gums containing antimicrobial agents
KR100414548B1 (en) * 2000-08-28 2004-01-07 황재관 Antibacterial composition for oral microorganisms using medicinal plant extracts and the extracting method thereof
US6531115B1 (en) * 2001-01-03 2003-03-11 Council Of Scientific & Industrial Research Analgesic and refreshing herbal composition and a process for preparing the same
JP4944309B2 (en) * 2001-05-18 2012-05-30 花王株式会社 Treatment for improving inflammation caused by periodontal disease
US6787675B2 (en) 2002-07-29 2004-09-07 Warner-Lambert Company Substituted tropolone compounds, oral care compositions containing the same and methods of using the same
US6689342B1 (en) 2002-07-29 2004-02-10 Warner-Lambert Company Oral care compositions comprising tropolone compounds and essential oils and methods of using the same
US7037535B2 (en) 2002-11-19 2006-05-02 Kimberly-Clark Worldwide, Inc. Method and composition for neutralizing house dust mite feces
US20050019379A1 (en) 2003-07-22 2005-01-27 Kimberly-Clark Worldwide, Inc. Wipe and methods for improving skin health
US8110215B2 (en) 2004-04-30 2012-02-07 Kimberly-Clark Worldwide, Inc. Personal care products and methods for inhibiting the adherence of flora to skin
JP4669683B2 (en) * 2004-09-09 2011-04-13 高砂香料工業株式会社 Antibacterial composition
JP5294536B2 (en) * 2005-03-31 2013-09-18 小林製薬株式会社 Gingival epithelial cell spreading inhibitor
BE1017325A3 (en) * 2006-09-27 2008-06-03 Siera Alexander Toothpaste, contains mosquito repellent substance preferably having an odor masking effect
JP2008161188A (en) * 2006-12-07 2008-07-17 Getto Chaya:Kk Functional beverage
CN108904345A (en) * 2017-12-26 2018-11-30 李文婷 A kind of oral cavity nursing agent with friction factor
CN109381384A (en) * 2017-12-26 2019-02-26 李文婷 A kind of oral cavity nursing agent containing friction factor
CN108904346A (en) * 2017-12-26 2018-11-30 李文婷 A kind of hemostasis oral cavity nursing agent containing friction factor
CN108904347A (en) * 2017-12-26 2018-11-30 李文婷 A kind of oral cavity nursing agent with friction function
KR102079529B1 (en) * 2018-07-02 2020-02-20 동의대학교 산학협력단 Oil composition for preventing and improving periodontal disease
KR102123321B1 (en) * 2018-07-02 2020-06-16 동의대학교 산학협력단 Oil composition for spherical cleaning
KR102123325B1 (en) * 2018-07-02 2020-06-16 동의대학교 산학협력단 Oil composition for preventing and improving periodontal disease
KR102123327B1 (en) * 2018-07-02 2020-06-16 동의대학교 산학협력단 Oil composition for spherical cleaning
JP2019131619A (en) * 2019-05-16 2019-08-08 株式会社日健総本社 Antibacterial agent
CN114869931A (en) * 2022-05-09 2022-08-09 浙江欣瑞达康生物医学技术有限公司 Application of sage flower extract

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5857320A (en) * 1981-10-01 1983-04-05 Tsurui Yakuhin Kogyo Kk Plaque formation inhibitor
JPS59175410A (en) * 1983-03-26 1984-10-04 Kanebo Shokuhin Kk Cariostatic agent
JPS63198616A (en) * 1987-02-13 1988-08-17 Yasutake Hichi Anticariogenic substance
JPH03109314A (en) * 1989-09-21 1991-05-09 Maruzen Kasei Co Ltd Anticarious agent
JPH03199314A (en) * 1989-12-27 1991-08-30 Masanori Iwase Decoppering method for iron scrap
JPH03255031A (en) * 1990-03-02 1991-11-13 Taiyo Koryo Kk Periodontosis preventing composition
JP2996838B2 (en) * 1993-07-12 2000-01-11 株式会社ポッカコーポレーション Antibacterial agent
JP3614479B2 (en) * 1993-11-10 2005-01-26 森下仁丹株式会社 Periodontal disease-causing bacteria or caries-causing bacteria inhibitor, oral composition and food containing them
JPH07309733A (en) * 1994-05-19 1995-11-28 Kanebo Ltd Composition for oral cavity

Also Published As

Publication number Publication date
WO1998044901A1 (en) 1998-10-15
NO985644D0 (en) 1998-12-03
AU6877398A (en) 1998-10-30
NO985644L (en) 1999-02-02
HUP0001257A2 (en) 2000-09-28
KR20000016351A (en) 2000-03-25
BR9804814A (en) 2000-01-25
JP2000512660A (en) 2000-09-26
NZ333146A (en) 2000-05-26
EP0921784A1 (en) 1999-06-16
CN1225576A (en) 1999-08-11
SK162898A3 (en) 1999-06-11
IL127259A0 (en) 1999-09-22
CZ384898A3 (en) 1999-04-14

Similar Documents

Publication Publication Date Title
AU727242B2 (en) Antimicrobial compositions
CA2257596A1 (en) Antimicrobial agents for oral hygiene products
KR101480690B1 (en) Oral composition containing natural agent
US5827503A (en) Method and composition for treating periodontitis
KR20170103476A (en) Composition for prevention or treatment of oral disease comprising ROSAE LAEVIGATAE Extract
KR20170037230A (en) Oral composition comprising cassava extract
KR102597684B1 (en) Oral composition comprising amaranth extract
Fareen et al. Evaluation of antimicrobial activity of commercially available herbal toothpaste-An in vitro study.
MXPA98010243A (en) Antimicrobial agents for oral hygiene products
KR102597685B1 (en) Oral composition comprising parsley extract
KR20170103482A (en) Composition for prevention or treatment of oral disease comprising Glechoma hederacea extract
KR20170103494A (en) Composition for prevention or treatment of oral disease comprising Melonis Pedicellus Extract
KR101818211B1 (en) Composition for prevention or treatment of oral disease comprising Arctill fructus Extract
MXPA98010244A (en) Antimicrobial compositions
KR20170142975A (en) Composition for prevention or treatment of oral disease comprising Leonurus sibiricus extract
KR20170120404A (en) Composition for prevention or treatment of oral disease comprising 2-methoxycinnamaldehyde
KR20170120408A (en) Composition for prevention or treatment of oral disease comprising Qucercetin 3-glucoside
KR20170120416A (en) Composition for prevention or treatment of oral disease comprising Matairesinol
KR20170120405A (en) Composition for prevention or treatment of oral disease comprising Arctiin
KR20170120411A (en) Composition for prevention or treatment of oral disease comprising Scopoletin
KR20170120399A (en) Composition for prevention or treatment of oral disease comprising Genistein
KR20170120414A (en) Composition for prevention or treatment of oral disease comprising Esculetin
KR20170118984A (en) Composition for prevention or treatment of oral disease comprising Leonurus sibiricus extract
KR20170103480A (en) Composition for prevention or treatment of oral disease comprising Kochiae Fructus Extract
KR20170103528A (en) Composition for prevention or treatment of oral disease comprising Gleditsiae fructus Extract

Legal Events

Date Code Title Description
FZDE Discontinued